Cargando…

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Geserick, P, Wang, J, Feoktistova, M, Leverkus, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385933/ https://www.ncbi.nlm.nih.gov/pubmed/25741598 http://dx.doi.org/10.1038/cddis.2015.55

Ejemplares similares

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2014)

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014)

Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1
por: Zall, Henry, et al.
Publicado: (2010)

A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML
por: Wang, Qing, et al.
Publicado: (2019)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]
Publicado: (2018)

Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression
por: Woo, S M, et al.
Publicado: (2014)

Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis
por: Yamaguchi, R, et al.
Publicado: (2011)

Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells
por: Zhu, Hong, et al.
Publicado: (2012)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells
por: Pandey, Manoj K., et al.
Publicado: (2013)

Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014)

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
por: Séveno, Céline, et al.
Publicado: (2012)

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway
por: Keuling, Angela M., et al.
Publicado: (2009)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022)

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment
por: Britt, Erin L., et al.
Publicado: (2019)

ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
por: Hwang, Eunjoo, et al.
Publicado: (2018)

Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin–NFAT pathway
por: Cippà, P E, et al.
Publicado: (2012)

Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737
por: Shahverdi, Mahshid, et al.
Publicado: (2020)

ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells
por: Xu, Yunjie, et al.
Publicado: (2018)

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC
por: Gilormini, Marion, et al.
Publicado: (2016)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
por: Lomovsky, Alexey, et al.
Publicado: (2020)

Genetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck
por: Zhou, Ziyuan, et al.
Publicado: (2012)

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer
por: Zinn, Rebekah L, et al.
Publicado: (2013)

By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737
por: Tailler, Maximilien, et al.
Publicado: (2018)

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
por: Risberg, Karianne, et al.
Publicado: (2011)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2011)

ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets
por: Shpakova, Valentina, et al.
Publicado: (2022)

BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
por: Quezada, María Josefina, et al.
Publicado: (2020)

Absence of RIPK3 predicts necroptosis resistance in malignant melanoma
por: Geserick, P, et al.
Publicado: (2015)

Corrigendum to “Data for the narrative skills of Urdu-speaking Preschoolers” [Data in Brief, 34 (2021) 106,737]
por: Hamdani, Saboor, et al.
Publicado: (2021)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014)

Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport
por: Velez, Juliana, et al.
Publicado: (2016)

Dimethyl celecoxib sensitizes gastric cancer cells to ABT‐737 via AIF nuclear translocation
por: Zhang, Bo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u4np7j2n80praosrjv4hjgr27l